In the immune-activation mouse model of neuroblastoma (GBM), copper chelation therapy with TEPA can reduce the PD-L1 expression of GBM, improve the anti-GBM immune response mediated via NK cells, and inhibit the immune checkpoint (Voli et al., 2020). This evidence concerns the gene CD274 and neuroblastoma.